Seeking Alpha

Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

WALTHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic (“PK”) ...
Nasdaq

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim ...
Nasdaq

Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, ...
Seeking Alpha

Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, Inc. for $4.10 per share, a 65% premium to last traded price, post-FDA approval of Unloxcyt for metastatic cutaneous ...
Business Wire

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, ...